Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies for serious and rare…
NeoGenomics Acquires Pathline to Strengthen Oncology Testing in the Northeast NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading provider of oncology testing services, has announced its acquisition of Pathline,…
Agomab Announces Positive Topline Phase 2a Interim Results for AGMB-129 in Fibrostenosing Crohn’s Disease Agomab Therapeutics NV (“Agomab”), a biotechnology company focused on developing innovative treatments for fibrotic diseases, has…
Virpax Explores MET Technology for Intranasal COVID-19 Vaccine Development Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative, non-addictive treatments for pain…
UroGen Pharma Reports Inducement Grants Under Nasdaq Rule 5635(c)(4) UroGen Pharma Ltd. (Nasdaq: URGN), a leading biotechnology company focused on developing and commercializing innovative therapies for urothelial and specialty cancers,…
NovaBay Pharmaceuticals Announces Special Stockholders Meeting NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) has officially announced the scheduling of a virtual Special Meeting on April 16, 2025.…
Sensorion Completes Patient Enrollment in NOTOXIS Phase 2a Clinical Trial of SENS-401 for Cisplatin-Induced Ototoxicity Prevention Sensorion, a pioneering clinical-stage biotechnology company focused on the development of innovative therapies for…
ENCell’s EN001 Granted FDA Orphan Drug Designation for Charcot-Marie-Tooth Disease ENCell, a pioneering biopharmaceutical company specializing in cell and gene therapy CDMO and novel drug development, announced that its investigational…
Arrowhead Highlights Clinical-Stage RNAi Therapies for Obesity and Metabolic Diseases Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) recently showcased promising preclinical data supporting the advancement of two first-in-class, RNA interference (RNAi)-based investigational…
Tris Pharma Reports Positive Phase 3 Results for Cebranopadol in Acute Pain Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company dedicated to developing innovative pain management therapies, has announced positive…
Frazier Life Sciences Names Gerald Nepom as Senior Advisor Frazier Life Sciences (FLS), a premier investment firm dedicated to advancing groundbreaking therapeutics, has appointed Gerald (Jerry) Nepom, M.D., Ph.D., as…
bioAffinity Cuts $4M in Costs to Boost CyPath® Lung Sales bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company dedicated to advancing noninvasive diagnostic solutions for early-stage lung cancer and…